Published Studies Related to Premarin Vaginal (Conjugated Estrogens Vaginal)
Well-designed clinical trials related to Premarin Vaginal (Conjugated Estrogens Vaginal)
A randomized, multiple-dose parallel study to compare the pharmacokinetic parameters of synthetic conjugated estrogens, A, administered as oral tablet or vaginal cream. [2011.04]
Preventing osteoporosis with a tissue selective estrogen complex (TSEC)
containing bazedoxifene/conjugated estrogens (BZA/CE). [2011]
Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. [2010.04]
A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. [2010.03]
Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal
women with symptoms of vulvar/vaginal atrophy. [2010]
A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. [2009.09.25]
Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. [2009.09]
Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally. [2009.07]
Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy. [2009.07]
A randomized study of low-dose conjugated estrogens on sexual function and quality of life in postmenopausal women. [2009.03]
A randomized study of low-dose conjugated estrogens on sexual function and quality of life in postmenopausal women. [2008.11.20]
Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women. [2008.10]
Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women. [2007.11.28]
Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study. [2006.11]
Randomized clinical trial comparing conjugated equine estrogens and isoflavones in postmenopausal women: a pilot study. [2006.01.10]
Relief of vasomotor symptoms and vaginal atrophy with three doses of conjugated estrogens and medroxyprogesterone acetate in postmenopausal Asian women from 11 countries: The Pan-Asia menopause (PAM) study. [2005.09.16]
Effect on sexual life--a comparison between tibolone and continuous combined conjugated equine estrogens and medroxyprogesterone acetate. [2005.04]
Treatment of atrophic vaginitis with topical conjugated equine estrogens in postmenopausal Asian women. [2004.09]
Body mass index does not influence response to treatment, nor does body weight change with lower doses of conjugated estrogens and medroxyprogesterone acetate in early postmenopausal women. [2004.05]
Low-dose (0.3 mg) synthetic conjugated estrogens A is effective for managing atrophic vaginitis. [2004.01.20]
A comparison of two different dosages of conjugated equine estrogen in continuous combined hormone replacement therapy with progestin. [2003.04]
The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers. [2003.03.14]
Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy. [2003.02]
Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy. [2003.01]
Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. [2002.05.22]
[Comparative study on two different dosages of conjugated equine estrogen continuously combined with medroxyprogesterone in prevention of postmenopausal osteoporosis] [2002.05]
The effect of estradiol vaginal tablet and conjugated estrogen cream on urogenital symptoms in postmenopausal women: a comparative study. [2001.10]
Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. [2001.06]
Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. [2001.06]
The comparison of effects of tibolone and conjugated estrogen-medroxyprogesterone acetate therapy on sexual performance in postmenopausal women. [2000.07.31]
17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. [2000.05]
Evaluation of conjugated estrogen plus medroxyprogesterone acetate versus tibolone in early postmenopausal Chinese women. [1999.05]
Comparison of Alora estradiol matrix transdermal delivery system with oral conjugated equine estrogen therapy in relieving menopausal symptoms. Alora Study Group. [1999.03]
The use of two estrogen preparations (a combined contraceptive pill versus conjugated estrogen cream) intravaginally to treat urogenital symptoms in postmenopausal Thai women: a comparative study. [1998.08]
Comparison of endometrial growth produced by unopposed conjugated estrogens or by micronized estradiol in postmenopausal women. [1997.01]
Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints. [1996.02]
Effects of conjugated equine oestrogens with and without the addition of cyclical medrogestone on hot flushes, liver function, blood pressure and endocrinological indices. [1990.03.17]
Well-designed clinical trials possibly related to Premarin Vaginal (Conjugated Estrogens Vaginal)
Plasma estrogen concentrations after oral and vaginal estrogen administration in women with atrophic vaginitis. [2010.11]
Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial. [2010.09]
Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex. [2010.09]
Tissue-selective agents: selective estrogen receptor modulators and the
tissue-selective estrogen complex. [2010]
Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. [2009.01]
Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome. [2009]
Health related quality of life after combined hormone replacement therapy: randomised controlled trial. [2008.08.21]
Endometrial effects of tibolone. [2007.03]
A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women. [2006.09]
Incidence of cervical cytological abnormalities with aging in the women's health initiative: a randomized controlled trial. [2006.08]
Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding. [2006.02]
Estrogen effects on the vaginal pH, flora and cytology in late postmenopause after a long period without hormone therapy. [2006]
Transdermal progesterone cream as an alternative progestin in hormone therapy. [2005.11]
Comparative controlled trial of a novel oral estrogen therapy, estradiol acetate, for relief of menopause symptoms. [2005.11]
The effects of hormone therapy, estrogen therapy and tibolone on apoptosis and cyclin D1 expression in postmenopausal vaginal epithelium. [2005.07.01]
Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. [2005.05]
The comparison of bleeding patterns with high-dose and low-dose hormone replacement therapy in postmenopausal women. [2004.08]
Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. [2004.04.07]
Estrogen plus progestin and colorectal cancer in postmenopausal women. [2004.03.04]
Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial. [2003.12]
Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. [2003.10.01]
Effect of raloxifene on sexual function in postmenopausal women. [2003.09]
Short-term urogenital effects of raloxifene, tamoxifen, and estrogen. [2003.07]
Menopausal symptoms in older women and the effects of treatment with hormone therapy. [2002.12]
Comparison of physical and emotional side effects of progesterone or medroxyprogesterone in early postmenopausal women. [2002.07]
Raloxifene versus continuous combined estrogen/progestin therapy: densitometric and biochemical effects in healthy postmenopausal Taiwanese women. [2001.12]
Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy. [2001.12]
Urinary tract infections in postmenopausal women: effect of hormone therapy and risk factors. [2001.12]
Ultrastructural aspects of the postmenopausal endometrium after oral or transdermal estrogen administration. [2001]
The positive predictive value of cervical smears in previously screened postmenopausal women: the Heart and Estrogen/progestin Replacement Study (HERS). [2000.12.19]
Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. [2000.06.27]
Clinical effects of a standardized soy extract in postmenopausal women: a pilot study. [2000.03]
A double-blind, randomized, comparative study evaluating clinical effects of two sequential estradiol-progestogen combinations containing either desogestrel or medroxyprogesterone acetate in climacteric women. [2000.02.15]
Bleeding pattern and endometrial changes during continuous combined hormone replacement therapy. The Ogen/Provera Study Group. [1998.05]
Randomized, double-blind, dose-ranging study of the endometrial effects of a vaginal progesterone gel in estrogen-treated postmenopausal women. [1997.10]
Vaginal ultrasound of the endometrium in postmenopausal women with symptoms of urogenital atrophy on low-dose estrogen or tibolone treatment: a comparison. [1997.01]
Comparison of two continuous combined estrogen progestogen regimens in postmenopausal women: a randomized trial. [1996.12]
Efficacy of estrogen supplementation in the treatment of urinary incontinence. The Continence Program for Women Research Group. [1996.11]
Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation. [1996.10]
Clinical trial of the estradiol vaginal ring in the U.S. [1995.12]
The effects of hormone substitution in depot form on the uterus in a group of 50 perimenopausal women--a vaginosonographic study. [1995.04]
A comparative study of two hormone replacement therapy regimens on safety and efficacy variables. [1995.04]
Continuous combined piperazine oestrone sulphate and medroxyprogesterone acetate hormone replacement therapy--a study of bleeding pattern, endometrial response, serum lipid and bone density changes. [1995.02]
Assessment of less than monthly progestin therapy in postmenopausal women given estrogen replacement. [1994.11]
Comparative study: Replens versus local estrogen in menopausal women. [1994.01]
Pilot trial of a gonadotropin hormone agonist with replacement hormones as a prototype contraceptive to prevent breast cancer. [1993.05]
Endometrial, physical and psychological effects of postmenopausal oestrogen therapy with added dydrogesterone. [1990.12]
A study of combined continuous ethinyl estradiol and norethindrone acetate for postmenopausal hormone replacement. [1990.02]
Endometrial and vaginal response to three different oestrogen preparations administered by the transdermal and oral routes. [1988.10]
Other research related to Premarin Vaginal (Conjugated Estrogens Vaginal)
Tissue-selective estrogen complex bazedoxifene and conjugated estrogens for the treatment of menopausal vasomotor symptoms. [2011.09.10]
Preventing osteoporosis with a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens (BZA/CE). [2011.02]
Tissue-selective estrogen complex bazedoxifene and conjugated estrogens for the
treatment of menopausal vasomotor symptoms. [2011]
Bazedoxifene when paired with conjugated estrogens is a new paradigm for treatment of postmenopausal women. [2010.12]
Aprela, a single tablet formulation of bazedoxifene and conjugated equine estrogens (Premarin) for the potential treatment of menopausal symptoms. [2010.04]
A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated
estrogens for treatment of moderate to severe vulvar/vaginal atrophy in
postmenopausal women. [2010]
Climacteric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses. [2007.03]
Effects of black cohosh (Cimicifuga racemosa) on bone turnover, vaginal mucosa, and various blood parameters in postmenopausal women: a double-blind, placebo-controlled, and conjugated estrogens-controlled study. [2006.03]
Effects of resveratrol, raloxifene, tibolone and conjugated equine estrogen on vaginal squamous cell maturation of ovariectomized rats. [2005]
Comparative effects of tibolone and conjugated equine estrogens with and without medroxyprogesterone acetate on the reproductive tract of female cynomolgus monkeys. [2002.07]
Vaginal administration of low-dose conjugated estrogens: systemic absorption and effects on the endometrium. [1994.08]
[Italian multicenter study for the verification of the efficacy and tolerability of short-term substitution hormone therapy using conjugated estrogens and progestagens administered orally in the postmenopausal a period] [1992.12]
Other possibly related research studies
Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. [2005.12.19]
Effects of estrogen with and without progestin on urinary incontinence. [2005.02.23]
Differences in vaginal dryness according to hormone therapy schedule using pH test strip in two groups of postmenopausal women. [2004.03]
|
